Share >  
Share
Share on Tumblr

Ranbaxy Pharmaceuticals Canada Inc

News »

   latest by relevance
Ranbaxy launches blood pressure pills in the US market
Dec 07, 2011 at 09:50 | Source: Moneycontrol.com
Ranbaxy Laboratories has launched an authorised generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from high blood pressure and high levels of cholesterol.
Glenmark Generics gets US FDA nod for hypertension drug
Aug 04, 2011 at 09:36 | Source: Moneycontrol.com
Glenmark Generics Inc USA, the unit of Glenmark Generics, has received final approval from the US Food and Drugs Administration (FDA) for its abbreviated new drug application (ANDA) to market its Verapamil extended-release tablets, which are indicated for management of essential hypertension.
Divine Skin inks distribution pact with Ranbaxy
Jul 19, 2011 at 20:48 | Source: PTI
US-based Divine Skin Inc today said it has entered into a pact with Ranbaxy Laboratories to sell its products used for treating hair loss through the Indian firm's distribution network.
USFDA opposes Mylan's injunction on Ranbaxy's Lipitor
Apr 07, 2011 at 11:02 | Source: CNBC-TV18
Ranbaxy is in focus again as the US Foods and Drugs Administration (USFDA) has filed an opposition to US-based pharmaceutical firm Mylan Inc's preliminary injunction on the launch of Ranbaxy's cholesterol treatment drug, which is a generic version of Pfizer's Lipitor, reports CNBC-TV18's Ekta Batra quoting sources.
Promius Pharma buys US rights of Cloderm cream
Apr 03, 2011 at 12:08 | Source: PTI
Promius Pharma LLC, an arm of Dr Reddy's Laboratories, today said it has bought the USA marketing rights of Cloderm (clocortolone pivalate 0.1%) cream manufactured by Canada-based Valeant Pharmaceuticals International, Inc.
Mylan sues FDA, seeks earlier Lipitor generic sale
Mar 22, 2011 at 10:07 | Source: Reuters
Mylan Inc has sued the US Food and Drug Administration to get generic versions of Pfizer Inc's Lipitor on the market in late June and block Ranbaxy from receiving 180 days of marketing exclusivity for its version of the medicine.

Videos »
USFDA opposes Mylan's injunction on Ranbaxy's Lipitor
Blocking Ranbaxy's launch of cholesterol drug, where is the logic?
Piramal Health to buy Biosyntech for USD 3.9 mn
Health Canada may clear Ranbaxy's generic Lipitor today
How global is India Inc?
more »

Photos »

  /  
News across the web »
Ranbaxy gets nod to market RAN-Rosuvastatin tablets
Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RPCI has received approval from Health Canada to manufacture and market RAN...
Mar 31, 2012 at 17:48 | Source: India Infoline
Ranbaxy gets Health Canada nod for cholesterol lowering drug
New Delhi, Mar 31: Ranbaxy Laboratories has received approval from Health Canada to manufacture and market its generic RAN-Rosuvastatin tablets used for lowering cholesterol in the Canadian market.&#...
Mar 31, 2012 at 14:56 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

Web Messenger

Platinum Member

107884 Followers

Ranbaxy Labs  

Source:The Hindu BusinessLine - New Delhi, Mar 31: Ranbaxy Laboratori...

11.20 AM Apr 2nd

a89

Gold Member

1 Followers

Ranbaxy Labs  

Ranbaxy Pharmaceuticals Canada Inc. (RPCI)...

1.31 PM Apr 1st

Related News »
Cipher Pharmaceuticals announces FDA approval of CIP-ISOTRETINOIN
MISSISSAUGA, ON, May 27, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND ... is also currently being reviewed by Health Canada . For more information, please visit www.cipherpharma.com. About Ranbaxy Laboratories Inc. Ranbaxy Laboratories ...
May 28, 2012 at 03:28 | Source: Yahoo Finance
Deciphering Cipher Pharma
(RTTNews) - In just another two weeks, Canada based Cipher Pharmaceuticals Inc ... In August 2008, Cipher Pharma granted Ranbaxy Pharmaceuticals Inc. exclusive right to market, sell and distribute CIP-Isotretinoin in the United States, its territories ...
May 14, 2012 at 07:55 | Source: RTT News

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window